Richella Ryan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Richella Ryan has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Anna Spathis
Primary Care Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
8 shared publications - Sara Booth
Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
5 shared publications Sara Booth
Cambridge University Hospitals NHS Foundation Trust, Palliative Care Department, Addenbrooke's Hospital, Hill's Road, Cambridge, CB2 0QQ, United Kingdom
4 shared publicationsAngela Clow
Psychophysiology and Stress Group, University of Westminster, Department of Psychology, 115 New Cavendish Street, London, W1W 6UW, United Kingdom
2 shared publications- Marie Fallon
Palliative Medicine, University of Edinburgh Western General Hospital, Edinburgh, UK
2 shared publications - Miriam J. Johnson
Wolfson Palliative Care Research Centre, Hull York Medical School, University of Hull, UK
2 shared publications
Latest Publications
- Open Access
- 1 May 2017
- Published by Elsevier in Psychoneuroendocrinology
- Vol. 79, 134-145
Salivary diurnal cortisol profiles in patients suffering from chronic breathlessness receiving supportive and palliative care services: A cross-sectional study
- 1 May 2017
- Published by Elsevier in Psychoneuroendocrinology
- Vol. 79, 134-145
Open AccessSalivary diurnal cortisol profiles in patients suffering from chronic breathlessness receiving supportive and palliative care services: A cross-sectional study
- Open Access
- 21 April 2017
- Published by Springer Nature in npj Primary Care Respiratory Medicine
- Vol. 27 (1) , 1-6
The Breathing, Thinking, Functioning clinical model: a proposal to facilitate evidence-based breathlessness management in chronic respiratory disease
Refractory breathlessness is a highly prevalent and distressing symptom in advanced chronic respiratory disease. Its intensity is not reliably predicted by the severity of lung pathology, with unhelpful emotions and behaviours inadvertently exacerbating and perpetuating the problem. Improved symptom management is possible if clinicians choose appropriate non-pharmacological approaches, but these require engagement and commitment from both patients and clinicians. The Breathing Thinking Functioning clinical model is a proposal, developed from current evidence, that has the potential to facilitate effective symptom control, by providing a rationale and focus for treatment.
- 21 April 2017
- Published by Springer Nature in npj Primary Care Respiratory Medicine
- Vol. 27 (1) , 1-6
Open AccessThe Breathing, Thinking, Functioning clinical model: a proposal to facilitate evidence-based breathlessness management in chronic respiratory disease
Refractory breathlessness is a highly prevalent and distressing symptom in advanced chronic respiratory disease. Its intensity is not reliably predicted by the severity of lung pathology, with unhelpful emotions and behaviours inadvertently exacerbating and perpetuating the problem. Improved symptom management is possible if clinicians choose appropriate non-pharmacological approaches, but these require engagement and commitment from both patients and clinicians. The Breathing Thinking Functioning clinical model is a proposal, developed from current evidence, that has the potential to facilitate effective symptom control, by providing a rationale and focus for treatment.
- 1 September 2016
- Published by Wolters Kluwer Health in Current Opinion in Supportive & Palliative Care
- Vol. 10 (3) , 242-248
Breathlessness and inflammation: potential relationships and implications
Purpose of review: Breathlessness and chronic inflammation both span a wide range of disease contexts and hold prognostic significance. The possibility of a causal relationship between the two has been hypothesized. The aims of this article are to review the intersections between breathlessness and inflammation in the literature, describe potential mechanisms connecting the two phenomena, and discuss the potential clinical implications of a causal relationship. Recent findings: There is a very limited literature exploring the relationship between systemic inflammation and breathlessness in chronic obstructive pulmonary disease, heart failure, and cancer. One large study in cancer patients is suggestive of a weak association between self-reported breathlessness and inflammation. Studies exploring the relationship between inflammation and Medical Research Council Dyspnoea grade in chronic obstructive pulmonary disease patients have produced inconsistent findings. Although a causal relationship has not yet been proven, there is evidence to support the existence of potential mechanisms mediating a relationship. This evidence points to a role for the skeletal muscle and stress hormone systems. Summary: There is much progress to be made in this area. Interventional studies, evaluating the impact of anti-inflammatory interventions on breathlessness, are needed to help determine whether a causal relationship exists. If proven, this relationship might have important implications for both the treatment and impact of breathlessness.
- 1 September 2016
- Published by Wolters Kluwer Health in Current Opinion in Supportive & Palliative Care
- Vol. 10 (3) , 242-248
Breathlessness and inflammation: potential relationships and implications
Purpose of review: Breathlessness and chronic inflammation both span a wide range of disease contexts and hold prognostic significance. The possibility of a causal relationship between the two has been hypothesized. The aims of this article are to review the intersections between breathlessness and inflammation in the literature, describe potential mechanisms connecting the two phenomena, and discuss the potential clinical implications of a causal relationship. Recent findings: There is a very limited literature exploring the relationship between systemic inflammation and breathlessness in chronic obstructive pulmonary disease, heart failure, and cancer. One large study in cancer patients is suggestive of a weak association between self-reported breathlessness and inflammation. Studies exploring the relationship between inflammation and Medical Research Council Dyspnoea grade in chronic obstructive pulmonary disease patients have produced inconsistent findings. Although a causal relationship has not yet been proven, there is evidence to support the existence of potential mechanisms mediating a relationship. This evidence points to a role for the skeletal muscle and stress hormone systems. Summary: There is much progress to be made in this area. Interventional studies, evaluating the impact of anti-inflammatory interventions on breathlessness, are needed to help determine whether a causal relationship exists. If proven, this relationship might have important implications for both the treatment and impact of breathlessness.
- 1 September 2016
- Published by Wolters Kluwer Health in Current Opinion in Supportive & Palliative Care
- Vol. 10 (3) , 228-235
Service delivery of complex interventions for refractory breathlessness
Purpose of review: The review considers the evidence for different service models existing for helping people manage the chronic, irreversible breathlessness that accompanies advanced disease. Recent findings: Many of the service models that are delivering care have not yet published their results in the scientific literature because these ideas, and the methods to evaluate them, are relatively new. There are three randomized controlled trials published which demonstrate the effectiveness of this approach and one which suggests that more episodes of some intervention components are not necessarily better. Summary: Breathlessness severity gives a better guide to a patient's prognosis than physiological measures in many diseases and the general population. Randomized controlled trial evidence confirms that a complex intervention for breathlessness can improve quality of life, reduce symptom impact, and support carers. Some preliminary data suggest prognosis improvement in some people. Integrated care is needed for both rapidly progressive disease, where death is inevitable, and chronic illness, when health improvement is possible.
- 1 September 2016
- Published by Wolters Kluwer Health in Current Opinion in Supportive & Palliative Care
- Vol. 10 (3) , 228-235
Service delivery of complex interventions for refractory breathlessness
Purpose of review: The review considers the evidence for different service models existing for helping people manage the chronic, irreversible breathlessness that accompanies advanced disease. Recent findings: Many of the service models that are delivering care have not yet published their results in the scientific literature because these ideas, and the methods to evaluate them, are relatively new. There are three randomized controlled trials published which demonstrate the effectiveness of this approach and one which suggests that more episodes of some intervention components are not necessarily better. Summary: Breathlessness severity gives a better guide to a patient's prognosis than physiological measures in many diseases and the general population. Randomized controlled trial evidence confirms that a complex intervention for breathlessness can improve quality of life, reduce symptom impact, and support carers. Some preliminary data suggest prognosis improvement in some people. Integrated care is needed for both rapidly progressive disease, where death is inevitable, and chronic illness, when health improvement is possible.
- Open Access
- 23 March 2016
- Published by Oxford University Press (OUP) in Annals of Behavioral Medicine
- Vol. 50 (2) , 210-236
Use of Salivary Diurnal Cortisol as an Outcome Measure in Randomised Controlled Trials: a Systematic Review
Background. Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis is associated with diverse adverse health outcomes, making it an important th
- 23 March 2016
- Published by Oxford University Press (OUP) in Annals of Behavioral Medicine
- Vol. 50 (2) , 210-236
Open AccessUse of Salivary Diurnal Cortisol as an Outcome Measure in Randomised Controlled Trials: a Systematic Review
Background. Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis is associated with diverse adverse health outcomes, making it an important th
- 22 October 2015
- Published by SAGE Publications in Palliative Medicine
- Vol. 30 (5) , 504-509
The importance of the feasibility study: Lessons from a study of the hand-held fan used to relieve dyspnea in people who are breathless at rest
Background: The dyspnea accompanying advanced cardiorespiratory disease is often refractory to palliation. It is disabling, distressing and associated with the diseases most common everywhere in the world. The hand-held fan, used to generate a draught across the face, is a simple, cost-effective, safe, and universally applicable palliative breathlessness intervention, consistently described as valuable in qualitative research. A previous crossover trial confirmed its benefit in patients breathless at rest, but the washout period was uncertain. Aim: To determine the washout period after use of the hand-held fan to inform accurate randomized controlled trial design. Design: An observational methodological study. Breathlessness intensity was measured using 100 mm visual analog scale and numerical rating scale, and “relief of breathlessness” was measured on a 5-point scale. Those benefitting from the fan provided visual analog scale/numerical rating scale scores until (1) scores returned to baseline values or (2) until response had plateaued. The primary outcome measure was the time (in minutes) to reach either component of the primary study endpoint. Settings/participants: Four in-/out-patient hospice/hospital units; participants had chronic refractory breathlessness using the fan. Results: Overall, 31 patients participated (mean age: 74.8 years; range: 49–98 years, standard deviation = 11.5 years); 64% were males. Approximately, half of the sample experienced benefit of moderate effect size. The relative reduction in breathlessness relative to the mean baseline score for the sample was 27% for the visual analog scale and 19% for the numerical rating scale. Conclusion: Feasibility work is essential, even for simple widely employed interventions.
- 22 October 2015
- Published by SAGE Publications in Palliative Medicine
- Vol. 30 (5) , 504-509
The importance of the feasibility study: Lessons from a study of the hand-held fan used to relieve dyspnea in people who are breathless at rest
Background: The dyspnea accompanying advanced cardiorespiratory disease is often refractory to palliation. It is disabling, distressing and associated with the diseases most common everywhere in the world. The hand-held fan, used to generate a draught across the face, is a simple, cost-effective, safe, and universally applicable palliative breathlessness intervention, consistently described as valuable in qualitative research. A previous crossover trial confirmed its benefit in patients breathless at rest, but the washout period was uncertain. Aim: To determine the washout period after use of the hand-held fan to inform accurate randomized controlled trial design. Design: An observational methodological study. Breathlessness intensity was measured using 100 mm visual analog scale and numerical rating scale, and “relief of breathlessness” was measured on a 5-point scale. Those benefitting from the fan provided visual analog scale/numerical rating scale scores until (1) scores returned to baseline values or (2) until response had plateaued. The primary outcome measure was the time (in minutes) to reach either component of the primary study endpoint. Settings/participants: Four in-/out-patient hospice/hospital units; participants had chronic refractory breathlessness using the fan. Results: Overall, 31 patients participated (mean age: 74.8 years; range: 49–98 years, standard deviation = 11.5 years); 64% were males. Approximately, half of the sample experienced benefit of moderate effect size. The relative reduction in breathlessness relative to the mean baseline score for the sample was 27% for the visual analog scale and 19% for the numerical rating scale. Conclusion: Feasibility work is essential, even for simple widely employed interventions.
- 27 April 2015
- Published by Taylor & Francis in Progress in Palliative Care
- Vol. 23 (6) , 326-330
What's trending in breathlessness research? Proceedings from the 8th Annual Meeting of the Breathlessness Research Interest Group
Breathlessness remains a challenging symptom, common to a multitude of malignant and non-malignant diseases, for which there are limited effective therapies once disease control is optimized. The American Thoracic Society (ATS) statement on dyspnoea reports that: (i) progress in dyspnoea management has not matched progress in elucidating underlying mechanisms; (ii) there is a critical need for interdisciplinary translational research to connect dyspnoea mechanisms with treatments; and (iii) there is a need to validate dyspnoea measures as patient-reported outcomes for clinical trials. Research into the many dimensions of breathlessness and its significance to patients and their carers has increased in recent years. This meeting is convened yearly to bring together researchers across various disciplines including respiratory medicine, anaesthetics, medical humanities, engineering, and palliative care, to further understanding of the symptom, discuss new techniques and advances in research, and pave the way forward for future studies and interventions. The presentations generated much vibrant discussion amongst the multidisciplinary attendees and highlighted areas where care for breathless patients could be improved. This is a positive time for breathlessness research, with several ATS research priorities being addressed and it is clear that further studies and ensuing interventions are on the horizon.
- 27 April 2015
- Published by Taylor & Francis in Progress in Palliative Care
- Vol. 23 (6) , 326-330
What's trending in breathlessness research? Proceedings from the 8th Annual Meeting of the Breathlessness Research Interest Group
Breathlessness remains a challenging symptom, common to a multitude of malignant and non-malignant diseases, for which there are limited effective therapies once disease control is optimized. The American Thoracic Society (ATS) statement on dyspnoea reports that: (i) progress in dyspnoea management has not matched progress in elucidating underlying mechanisms; (ii) there is a critical need for interdisciplinary translational research to connect dyspnoea mechanisms with treatments; and (iii) there is a need to validate dyspnoea measures as patient-reported outcomes for clinical trials. Research into the many dimensions of breathlessness and its significance to patients and their carers has increased in recent years. This meeting is convened yearly to bring together researchers across various disciplines including respiratory medicine, anaesthetics, medical humanities, engineering, and palliative care, to further understanding of the symptom, discuss new techniques and advances in research, and pave the way forward for future studies and interventions. The presentations generated much vibrant discussion amongst the multidisciplinary attendees and highlighted areas where care for breathless patients could be improved. This is a positive time for breathlessness research, with several ATS research priorities being addressed and it is clear that further studies and ensuing interventions are on the horizon.
- 1 September 2014
- Published by Wolters Kluwer Health in Current Opinion in Supportive & Palliative Care
- Vol. 8 (3) , 200-207
Correlates between basic science and therapeutic interventions
Purpose of review To review the science of breathlessness and demonstrate how current therapeutic interventions for breathlessness target the known underlying mechanisms. Recent findings There is increasing evidence that breathlessness is experienced in multiple dimensions. The underlying mechanisms relate to the perceptual processes involved, the emotional response and the functional impact. The theory that breathlessness is perceived when there is a mismatch between the central drive to breathe and the level of ventilation remains a central concept, providing a useful theoretical framework around which many current therapies have been developed. The sites involved in the corticolimbic processing of breathlessness have been identified, though little is known about the neural pathways involved. Summary Therapies which aim to reduce the neural respiratory drive include oxygen, exercise and opioids. Interventions which aim to improve ventilation include breathing retraining and positioning. Modulation of respiratory afferent feedback may be achieved using chest wall vibration and fan therapy. Cognitive and behavioural therapies aim to modify the emotional response to breathlessness. Opioids have been shown to modulate breathlessness at the level of the corticolimbic system, as well as the brainstem. Further work is needed to identify other relevant neurotransmitter systems in order to explore new therapies.
- 1 September 2014
- Published by Wolters Kluwer Health in Current Opinion in Supportive & Palliative Care
- Vol. 8 (3) , 200-207
Correlates between basic science and therapeutic interventions
Purpose of review To review the science of breathlessness and demonstrate how current therapeutic interventions for breathlessness target the known underlying mechanisms. Recent findings There is increasing evidence that breathlessness is experienced in multiple dimensions. The underlying mechanisms relate to the perceptual processes involved, the emotional response and the functional impact. The theory that breathlessness is perceived when there is a mismatch between the central drive to breathe and the level of ventilation remains a central concept, providing a useful theoretical framework around which many current therapies have been developed. The sites involved in the corticolimbic processing of breathlessness have been identified, though little is known about the neural pathways involved. Summary Therapies which aim to reduce the neural respiratory drive include oxygen, exercise and opioids. Interventions which aim to improve ventilation include breathing retraining and positioning. Modulation of respiratory afferent feedback may be achieved using chest wall vibration and fan therapy. Cognitive and behavioural therapies aim to modify the emotional response to breathlessness. Opioids have been shown to modulate breathlessness at the level of the corticolimbic system, as well as the brainstem. Further work is needed to identify other relevant neurotransmitter systems in order to explore new therapies.
- 31 July 2014
- Published by Elsevier in Medical Hypotheses
- Vol. 83 (2) , 232-237
The biological impact of living with chronic breathlessness - A role for the hypothalamic-pituitary-adrenal axis?
- 31 July 2014
- Published by Elsevier in Medical Hypotheses
- Vol. 83 (2) , 232-237
The biological impact of living with chronic breathlessness - A role for the hypothalamic-pituitary-adrenal axis?